Who eyes vaccine trial for ebola hit dr congo
There have been several vaccine trials conducted in the Democratic Republic of Congo (DRC) to combat the ongoing Ebola outbreak. Here are a few examples:
- rVSV-ZEBOV vaccine: In 2018, the World Health Organization (WHO) and the DRC Ministry of Health launched a vaccination campaign using the rVSV-ZEBOV vaccine, developed by Merck, Sharp & Dohme (MSD). The vaccine was shown to be highly effective in preventing Ebola in clinical trials and has been used to vaccinate thousands of people in the DRC.
- Ad26.ZEBOV vaccine: In 2019, the DRC government, in collaboration with the WHO and the biotech company Janssen Pharmaceuticals, launched a clinical trial to test the Ad26.ZEBOV vaccine, which is also designed to protect against Ebola. The trial aimed to evaluate the safety and efficacy of the vaccine in preventing Ebola in adults and children.
- mRNA-1273 vaccine: In 2020, the National Institute of Allergy and Infectious Diseases (NIAID) and the DRC government launched a clinical trial to test the mRNA-1273 vaccine, developed by Moderna Therapeutics, against Ebola. The trial aimed to evaluate the safety and efficacy of the vaccine in preventing Ebola in adults and children.
These vaccine trials have been conducted in collaboration with various international organizations, including the WHO, the Centers for Disease Control and Prevention (CDC), and the NIAID, as well as local health authorities and research institutions in the DRC.
It's worth noting that the Ebola outbreak in the DRC has been ongoing since 2018, and the response has involved a range of measures, including vaccination, contact tracing, and infection prevention and control. The use of vaccines has been a critical component of the response, and the data collected from these trials has helped inform public health strategies to combat the outbreak.